BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 12742021)

  • 1. Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors.
    Katz BA; Elrod K; Verner E; Mackman RL; Luong C; Shrader WD; Sendzik M; Spencer JR; Sprengeler PA; Kolesnikov A; Tai VW; Hui HC; Breitenbucher JG; Allen D; Janc JW
    J Mol Biol; 2003 May; 329(1):93-120. PubMed ID: 12742021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
    Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
    J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of multicentered short hydrogen bond arrays to potency of active site-directed serine protease inhibitors.
    Katz BA; Spencer JR; Elrod K; Luong C; Mackman RL; Rice M; Sprengeler PA; Allen D; Janc J
    J Am Chem Soc; 2002 Oct; 124(39):11657-68. PubMed ID: 12296731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
    Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
    Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
    Katz BA; Mackman R; Luong C; Radika K; Martelli A; Sprengeler PA; Wang J; Chan H; Wong L
    Chem Biol; 2000 Apr; 7(4):299-312. PubMed ID: 10779411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recruiting Zn2+ to mediate potent, specific inhibition of serine proteases.
    Katz BA; Luong C
    J Mol Biol; 1999 Sep; 292(3):669-84. PubMed ID: 10497030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the structures of the cyclotheonamide A complexes of human alpha-thrombin and bovine beta-trypsin.
    Ganesh V; Lee AY; Clardy J; Tulinsky A
    Protein Sci; 1996 May; 5(5):825-35. PubMed ID: 8732754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
    Katz BA; Luong C; Ho JD; Somoza JR; Gjerstad E; Tang J; Williams SR; Verner E; Mackman RL; Young WB; Sprengeler PA; Chan H; Mortara K; Janc JW; McGrath ME
    J Mol Biol; 2004 Nov; 344(2):527-47. PubMed ID: 15522303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa.
    Verner E; Katz BA; Spencer JR; Allen D; Hataye J; Hruzewicz W; Hui HC; Kolesnikov A; Li Y; Luong C; Martelli A; Radika K; Rai R; She M; Shrader W; Sprengeler PA; Trapp S; Wang J; Young WB; Mackman RL
    J Med Chem; 2001 Aug; 44(17):2753-71. PubMed ID: 11495587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent, multi-target serine protease inhibition achieved by a simplified β-sheet motif.
    Chen X; Riley BT; de Veer SJ; Hoke DE; Van Haeften J; Leahy D; Swedberg JE; Brattsand M; Hartfield PJ; Buckle AM; Harris JM
    PLoS One; 2019; 14(1):e0210842. PubMed ID: 30668585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.
    Mackman RL; Katz BA; Breitenbucher JG; Hui HC; Verner E; Luong C; Liu L; Sprengeler PA
    J Med Chem; 2001 Nov; 44(23):3856-71. PubMed ID: 11689072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
    Bhunia SS; Roy KK; Saxena AK
    J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly selective mechanism-based thrombin inhibitors: structures of thrombin and trypsin inhibited with rigid peptidyl aldehydes.
    Krishnan R; Zhang E; Hakansson K; Arni RK; Tulinsky A; Lim-Wilby MS; Levy OE; Semple JE; Brunck TK
    Biochemistry; 1998 Sep; 37(35):12094-103. PubMed ID: 9724521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factorising ligand affinity: a combined thermodynamic and crystallographic study of trypsin and thrombin inhibition.
    Dullweber F; Stubbs MT; Musil D; Stürzebecher J; Klebe G
    J Mol Biol; 2001 Oct; 313(3):593-614. PubMed ID: 11676542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
    Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
    J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of benzothiazole guanidines as novel inhibitors of thrombin and trypsin IV.
    Karle M; Knecht W; Xue Y
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4839-43. PubMed ID: 22726924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.
    Sperl S; Jacob U; Arroyo de Prada N; Stürzebecher J; Wilhelm OG; Bode W; Magdolen V; Huber R; Moroder L
    Proc Natl Acad Sci U S A; 2000 May; 97(10):5113-8. PubMed ID: 10805774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of the RWJ-51084-bovine pancreatic beta-trypsin complex at 1.8 A.
    Recacha R; Carson M; Costanzo MJ; Maryanoff B; DeLucas LJ; Chattopadhyay D
    Acta Crystallogr D Biol Crystallogr; 1999 Nov; 55(Pt 11):1785-91. PubMed ID: 10531473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.
    Mackman RL; Hui HC; Breitenbucher JG; Katz BA; Luong C; Martelli A; McGee D; Radika K; Sendzik M; Spencer JR; Sprengeler PA; Tario J; Verner E; Wang J
    Bioorg Med Chem Lett; 2002 Aug; 12(15):2019-22. PubMed ID: 12113832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular design and characterization of an alpha-thrombin inhibitor containing a novel P1 moiety.
    Malikayil JA; Burkhart JP; Schreuder HA; Broersma RJ; Tardif C; Kutcher LW; Mehdi S; Schatzman GL; Neises B; Peet NP
    Biochemistry; 1997 Feb; 36(5):1034-40. PubMed ID: 9033393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.